Chest
Volume 133, Issue 6, June 2008, Pages 1296-1298
Journal home page for Chest

Editorials
Biomarkers in COPD: Are We There Yet?

https://doi.org/10.1378/chest.08-0455Get rights and content

References (15)

There are more references available in the full text version of this article.

Cited by (20)

  • Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomised controlled trial

    2012, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    The complex inflammatory pathways involved in COPD have become the focus of drug development efforts in recent years [2,8,9]. Successful development of new therapeutic agents has been hampered to an extent by a lack of suitable local and systemic biomarkers of the pathogenic processes in COPD [1,6,10,11]. An ideal biomarker would be a direct indicator of the process being studied, be associated with a clinically important outcome such as mortality, be reproducible, easily measured and sensitive to effective interventions aimed at the target outcomes of interest in COPD [1,6,11].

  • Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: A randomised controlled 6-week trial

    2011, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    The efficacy signals that were evaluated in this study were directed at two possible actions of the drug in COPD. The first signal set looked at the ability of AZD1236 to inhibit the inflammatory response already documented in COPD using a panel of biomarkers thought to be relevant to the pathogenesis of the condition [27,28] and the second signal looked for inhibition of the elastase activity that MMP-12 is thought to exert. In a pre-clinical model of smoke-induced emphysema in the guinea pig, a combined MMP-9/MMP-12 inhibitor reduced serum TNF-α after 1 month’s therapy and the effect was maintained over the 6-months examined [11].

  • Biomarkers in COPD

    2010, Pulmonary Pharmacology and Therapeutics
View all citing articles on Scopus

Both authors have received honoraria for speaking engagements from GlaxoSmithKline and AstraZeneca and for consultative services from GlaxoSmithKline.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).

1

Dr. Sin is an Associate Professor of Medicine and a Canada Research Chair in COPD at the University of British Columbia, and a Senior Scholar with the Michael Smith Foundation for Health Research.

2

Dr. Man is a Professor of Medicine at the University of British Columbia.

View full text